2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Page 1 of 18 NEW ZEALAND DATA SHEET 1. PRODUCT NAME SmofKabiven® Electrolyte Free (Infusion, emulsion) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SmofKabiven Electrolyte Free is a three chamber bag system of amino acid solution, glucose solution
Download 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Diagnosis and Follow-up of Multiple Myeloma and …
camlt.orgLearning Objectives • Compare traditional myeloma testing methods with current recommended protocols and describe how kappa & lambda free light chain …
IMWG criteria - myeloma.gr.jp
myeloma.gr.jpprogression or progression-free survival. 6 For progressive disease, serum M-component increases of >1 gm/dL are sufficient to define relapse if starting M-component is >5 g/dL.
Amyloidosis Information A General Overview for …
www.amyloidosis.orgcells, platelets and antibodies (which are proteins). In the case of AL amyloidosis, the bone marrow plasma cells produce mis-folded antibody protein fragments (parts of antibodies called “light chains”)
IHC Handbook Table of Contents
www.ihcworld.com6 ANTIBODIES domains (C). Each domain contains 110 to 120 amino acids and one intrachain disulfide bond. On the variable domain of the light chain …
KAPPA HAFİF ZİNCİR MİYELOMU - journalagent.com
www.journalagent.comtepecik eğit hast derg 2014; 24 (3): 203-205 203 olgu sunumu klİnİk araŞtirma deneysel ÇaliŞma 1 kappa hafİf zİncİr mİyelomu kappa light chain myeloma İsmail atasoy
Multiple myeloma – lenalidomide Initial PBS …
www.perthhaematology.com.au4203.1209 1 of 4 Multiple myeloma – lenalidomide Initial PBS authority application and supporting information Purpose of this form You must lodge this form for a patient starting initial Pharmaceutical
Understanding your MULTIPLE MYELOMA LAB TESTS
www.velcade.com3 Mark the test values in the column below each date Reference ranges Date of laboratory test SERUM QUANTITATIVE IMMUNOGLOBULINS (Igs) Pages 9-10